+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Low risk of severe hypoglycemia in type-1-diabetes with residual c-peptide and intensive insulin therapy



Low risk of severe hypoglycemia in type-1-diabetes with residual c-peptide and intensive insulin therapy



Diabetes 48(SUPPL 1): A124




(PDF emailed within 1 workday: $29.90)

Accession: 035243037

Download citation: RISBibTeXText


Related references

Flexible intensive insulin therapy in adults with type 1 diabetes and high risk for severe hypoglycemia and diabetic ketoacidosis. Diabetes Care 29(10): 2196-2199, 2006

Flexible Intensive Insulin Therapy in Adults With Type 1 Diabetes and High Risk for Severe Hypoglycemia and Diabetic Ketoacidosis: Response to Pennant et al. Diabetes Care 30(3): e5-e6, 2007

Flexible intensive insulin therapy in adults with type 1 diabetes and high risk for severe hypoglycemia and diabetic ketoacidosis: response to Sämann et al. Diabetes Care 30(3): E4; Author Reply E5-6, 2007

Insulin lispro lowers the incidence of severe hypoglycemia, without a detrimental effect on glycemic control, in those individuals with type 1 diabetes at high risk of severe hypoglycemia. Diabetes 48(SUPPL 1): A122, 1999

Comparison of glucose control and hypoglycemia risk in patients with type i diabetes mellitus on conventional vs. intensive vs. continuous subcutaneous insulin infusion therapy. Diabetes Research & Clinical Practice (SUPPL 1): S211-S212, 1985

Lower severe hypoglycemia risk: insulin glargine versus NPH insulin in type 2 diabetes. American Journal of Managed Care 14(1): 25-30, 2008

Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care 23(5): 639-643, 2000

Association of Insulin Pump Therapy vs Insulin Injection Therapy With Severe Hypoglycemia, Ketoacidosis, and Glycemic Control Among Children, Adolescents, and Young Adults With Type 1 Diabetes. JAMA 318(14): 1358-1366, 2017

Postprandial insulin profiles with implantable pump therapy may explain decreased frequency of severe hypoglycemia, compared with intensive subcutaneous regimens, in insulin-dependent diabetes mellitus patients. American Journal of Medicine 100(4): 412-417, 1996

Uncoupling intensive insulin therapy from weight gain and hypoglycemia in type 1 diabetes. Diabetes Technology and Therapeutics 13(4): 457-460, 2011

Risk factors of severe hypoglycemia in type 1 insulin dependent diabetes. Diabetologia 27(2): 306A, 1984

Residual β-Cell function 3-6 years after onset of type 1 diabetes reduces risk of severe hypoglycemia in children and adolescents. Diabetes Care 36(11): 3454-3459, 2015

Symptoms of hypoglycemia in a prospective cohort of 686 patients with type 2 diabetes mellitus on intensive insulin therapy. Diabetologia 45(Suppl. 2): A 267, 2002

Intensive insulin therapy reduces counterregulatory hormone responses to hypoglycemia in patients with type I diabetes. Annals of Internal Medicine 103(2): 184-190, 1985

Sustained efficacy of continuous subcutaneous insulin infusion in type 1 diabetes subjects with recurrent non-severe and severe hypoglycemia and hypoglycemia unawareness: a pilot study. Diabetes Technology and Therapeutics 12(7): 517-521, 2010